Tadalafil 5mg tablets

IntroductionErectile dysfunction (ED) is a multifactorial condition with psychological, vascular, hormonal, neurological, and systemic risk factors. Four phosphodiesterase-5 inhibitors (PDE5is), sildenafil, tadalafil, vardenafil, and avanafil, have been approved by the United States Food and Drug Administration and the European Medicines Agency for the management of ED.ObjectivesWhile several meta-analyses have assessed the efficacy of PDE5is in the management of ED, none have focused on dose-specific outcomes. Hence, the study was conducted to compare the dose-dependent efficacy and safety of four FDA/EMA-approved PDE5is in the treatment of ED using on-demand dosages.MethodsA comprehensive literature search identified randomized, double-blind, placebo-controlled trials. Only on-demand doses of PDE5is were included in the network meta-analysis (NMA), which focused on primary outcomes such as the proportion of participants achieving satisfactory erectile function (EF), defined as an International Index of Erectile Function (IIEF) domain score > 26. A threshold analysis was conducted to evaluate the robustness of treatment recommendations derived from the NMA.ResultsA total of 83 studies with 6029 participants (treatment group: 3457 participants; placebo group: 2572 participants) were included. This dose-response network meta-analysis highlighted better efficacy with sildenafil (sildenafil 100 mg: odds ratio [OR] 9.06, sildenafil 50 mg: OR 7.90) in improving EF compared to that with placebo, followed by tadalafil (tadalafil 20 mg: OR 7.13, tadalafil 10 mg: OR 3.14), vardenafil (vardenafil 10 mg: OR 7.78), and avanafil (avanafil 200 mg: OR 3.42, avanafil 100 mg: OR 1.75). Threshold analysis showed a statistically significant improvement in ED with sildenafil 100 mg [OR 2.20; 95% confidence interval (CI) 1.78-2.63] and 50 mg (OR 2.10; 95% CI 1.69-2.50) compared to placebo. This indicated the robustness of the results, with moderate variations unlikely to alter their comparative ranking within the NMA. The odds of treatment-related adverse events were highest for vardenafil, followed by avanafil and sildenafil, and lowest for tadalafil compared to placebo. However, in some instances, the wide CI showed higher variability and potential uncertainty in effect estimates.ConclusionPDE5is are highly effective, with sildenafil showing a significantly greater efficacy compared with the other PDE5is.

Abstract licence: CC BY-NC

PurposeErectile dysfunction (ED) is a prevalent and distressing consequence of radical prostatectomy (RP) and radiotherapy (RT) for prostate cancer, profoundly impacting quality of life. Despite a wide array of available interventions, their comparative effectiveness remains uncertain in the absence of head-to-head trials.Materials and methodsWe conducted a systematic review and network meta-analysis (NMA) of studies evaluating medical interventions for ED following RP or RT. MEDLINE, Embase, and Scopus were searched for eligible studies. Risk of bias (RoB) was assessed using the Cochrane RoB 2 and ROBINS-I tools. A random-effects NMA was performed, with efficacy expressed as odds ratios (ORs) and 95% confidence intervals (CIs). The certainty of evidence was evaluated using the GRADE framework. The primary outcome was recovery of erectile function, assessed using validated measures or the proportion achieving successful intercourse.ResultsForty-one studies (n=4,157 participants) met inclusion criteria. Following RP, combination therapies were most effective: tadalafil plus intraurethral alprostadil gel (OR 24.8), tadalafil plus vacuum erection device (OR 12.3), and tadalafil plus low-intensity shockwave therapy (OR 8.2) demonstrated the highest odds of functional recovery versus placebo. Following RT, on-demand tadalafil was the most effective intervention (OR 8.0). Pooled analysis of RP studies showed a significant mean improvement in International Index of Erectile Function scores favouring active interventions over control (mean difference 4.5, 95% CI: 2.4-6.5, I²=62%), with longer intervention duration associated with greater improvement. Overall certainty of evidence was low to very low due to RoB, imprecision, and inconsistency.ConclusionsCombination therapies appear most effective for ED recovery after RP, while on-demand phosphodiesterase type 5 inhibitors are most efficacious after RT. These findings provide novel comparative evidence; however, cautious clinical application and further high-quality research are warranted.

Abstract licence: CC BY-NC

IntroductionPeyronie's disease (PD) is an acquired fibrotic disorder of the tunica albuginea that can cause pain, curvature, deformity, erectile dysfunction, and substantial psychosexual burden. Management is usually guided by disease phase, yet active disease remains inconsistently defined, and no oral regimen has shown high-certainty disease-modifying efficacy. We synthesize clinical, mechanistic, guideline, outcome-measure, traction, and public-data evidence relevant to active or progressive PD as a target for early antifibrotic trials.MethodsWe conducted a targeted narrative translational review of full-text sources on active-phase definitions, PDE5 inhibitor/selective estrogen receptor modulator (SERM) pharmacology, tadalafil-based clinical studies, placebo-controlled tamoxifen evidence, current recommendations, non-surgical evidence reviews, patient-reported outcome measures, traction therapy, and PD transcriptomic or single-cell studies. We selected sources through targeted database searching, citation chasing, and full-text evidence audit; no protocol-registered systematic review was performed. Clinical studies were heterogeneous and largely non-randomized; therefore, we did not attempt a pooled efficacy estimate.ResultsActive and stable PD remain clinically useful categories, although their operational definitions vary across studies. Experimental PD models identify fibroblast-to-myofibroblast transformation as a pharmacologically accessible process, with PDE5 inhibitors and SERMs showing timing-dependent antifibrotic effects. Retrospective PDE5 inhibitor studies and clinical audits of PDE5 inhibitor plus tamoxifen therapy report mixed observations on progression and pain, but interpretation is constrained by non-randomized design, small or imbalanced controls, confounding, and heterogeneous endpoints. Placebo-controlled monotherapy evidence remains negative or neutral for tamoxifen, especially when disease duration is broad or not stratified by active inflammatory features. Guidelines and evidence reviews support individualized conservative care without endorsing PDE5 inhibitor/SERM therapy as standard practice.ConclusionActive/progressive PD is a defensible setting for early antifibrotic trials. PDE5 inhibitor/SERM therapy is among the best-developed mechanistic candidates, but remains investigational. Clinical adoption requires prospective, randomized, stage-defined studies with standardized curvature assessment, plaque imaging, erectile-function measurement, pain assessment, co-intervention documentation, adverse-event capture, and PD-specific patient-reported outcomes.

Abstract licence: CC BY

IntroductionSudden sensorineural hearing loss (SSNHL) can significantly impact quality of life. Recent studies propose a link between the use of phosphodiesterase-5 inhibitors (PDE-5is) and SSNHL emergence.ObjectiveTo clarify the relationship between PDE-5i use and the risk of SSNHL development.Data synthesisFollowing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, two independent reviewers searched the PubMed, Embase, and Web of Science databases for articles up to December 2023 on hearing loss in PDE-5i users. Out of 190 abstracts initially identified, 6 met the inclusion criteria, totaling 54 patients aged between 37 and 62 years. One study involved 4 female participants, while the rest focused on 50 male patients. Sildenafil, vardenafil, and tadalafil were the most commonly used PDE-5is. All patients experienced sensorineural hearing loss, ranging from moderate to profound, with 4 patients (7%) noting tinnitus and 3 patients (5%), vertigo, in addition to the hearing loss. One patient experienced bilateral hearing loss 15 days after initiating sildenafil consumption. Corticosteroid therapy was the exclusive treatment in all cases. The long-term outcomes following the cessation of the medication were available in 7 cases: 4 patients (57%) had no improvement, 2 patients (29%) fully recovered, and 1 patient (14%) had incomplete resolution of the hearing loss.ConclusionThe current systematic review underscores the importance of monitoring hearing in PDE5i patients and advising them about the potential risk. Further research with larger samples and control groups is needed to establish a definitive causal link.

Abstract licence: CC BY